Roche
Europe approves first therapy for haemophilia A with inhibitors in over 20 years
March 1, 2018Research and Development Europe, European Commission, Hemlibra, Roche, haemophilia, pharma
Roche has revealed that its bispecific factor IXa- and factor X-directed antibody Hemlibra (emicizumab) has been approved by the European …
Top Ten most popular articles on Pharmafile.com this week
February 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's disease, Roche, Top 10 news, Top ten news, Trump, biotech, drugs, pharma, pharmaceutical
Another week is finished and it’s been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of …
Roche boosts cancer efforts with $1.9 billion buyout of Flatiron Health
February 16, 2018Medical Communications, Sales and Marketing Cancer, Flatiron health, Roche, acquisition, oncology, pharma
Roche has announced it is to acquire privately held healthcare and technology firm Flatiron Health for $1.9 billion to leverage …
New flu med can destroy influenza virus in one day
February 13, 2018Manufacturing and Production, Research and Development Roche, Shionongi, Tamiflu, biotech, drugs, flu, influenza, pharma, pharmaceutical
Researchers in Japan have achieved a notable success in a Phase 3 clinical trial to determine whether a new vaccine …
NICE backtracks to recommend Roche’s Gazyvaro in follicular lymphoma
February 12, 2018Sales and Marketing Gazyvaro, NHS, NICE, Roche, follicular lymphoma
Roche has announced that NICE has issued its final decision to recommend the use of its Gazyvaro (obinutuzumab). The glyco-engineered …
Array’s melanoma therapy blasts Roche’s out of water
February 7, 2018Research and Development Array Biopharma, Pierre Fabre, Roche, biotech, drugs, melanoma, pharma, pharmaceutical
Array Biopharma suffered a serious knock back in early 2017 when its plan to commercialise its drug, binimetinib, were derailed …
NICE approves Perjeta for routine use on NHS
February 1, 2018Sales and Marketing Perjeta, Roche, biotech, drugs, pharma, pharmaceutical
NICE has given the nod to Roche’s Perjeta for routine first-line use, alongside Herceptin and chemotherapy, in patients with HER2-positive …
EMA committee recommends seven therapies from Roche, GSK, MSD and more
January 29, 2018Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …
Abcam acquires rights to over 700 Roche products in new licensing deal
January 22, 2018Sales and Marketing Abcam, Roche, partnership, pharma
Roche has entered a licensing agreement Abcam which gives the British biotech exclusive access to the marketing rights for 760 …
Roche’s Ocrevus gets the go ahead in Europe for two forms of MS
January 12, 2018Medical Communications, Sales and Marketing Europe, European Commission, Ocrevus, Roche, multiple sclerosis, pharma
Roche has revealed that its multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has been awarded marketing approval in Europe by the …
Roche boosts oncology portfolio with $1.7bn acquisition
December 22, 2017Medical Communications, Sales and Marketing Roche, biotech, drugs, ignyta, pharma, pharmaceutical
Roche has announced that it will buy Ignyta, a San Diego-based biotech that has a pipeline of oncology drugs, for …
FDA grants breast cancer approval to Roche’s Perjeta/Herceptin combo therapy
December 21, 2017Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche has announced that the FDA has granted approval to Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and a (Perjeta-based) …
Working Life: Dr Rav Seeruthun, Medical Director of Roche UK
December 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical
Pharmafile.com sat down with Dr Rav Seeruthun, Medical Director of Roche UK, to discuss his career thus far and the lessons …
Ionis scores huge breakthrough in Huntington’s, Roche licenses drug
December 12, 2017Manufacturing and Production, Research and Development Ionis, Roche, biotech, drugs, pharma, pharmaceutical
Ionis Pharmaceuticals has revealed findings from its Phase 1/2a study into a treatment for Huntington’s disease and the strong data …
Roche Tecentriq combo effective, but is it enough?
December 8, 2017Medical Communications, Research and Development Roche, biotech, drugs, pharma, pharmaceutical, tecentriq
When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-free survival …
Latest content
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
